Watch the interview with Prostatype Genomics vd Fredrik Persson hereinafter.
This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in the EU Growth Prospectus which was published and published on prostatypegenomics.com on 24 April 2023. The EU Growth Prospectus has been approved and registered by the Swedish Financial Supervisory Authority. The marketing material is not intended to replace the EU Growth Prospectus as a basis for a decision to subscribe for shares in Prostatype Genomics and does not constitute a recommendation to subscribe for shares in Prostatype Genomics. Investors intending or considering investing in Prostatype Genomics are therefore advised to read the EU Growth Prospectus.